Medgenics Announces Public Offering of Common Stock
September 30, 2015 16:01 ET
|
Medgenics, Inc.
PHILADELPHIA, Sept. 30, 2015 (GLOBE NEWSWIRE) -- Medgenics, Inc. (NYSE MKT:MDGN) today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. The...
Medgenics Acquires Phase 2-Ready CNS Program: NFC-1
September 09, 2015 08:30 ET
|
Medgenics, Inc.
Strong Efficacy Signal Established in Genetically Identified Subset of ADHD Patients
Development will Include Neuropsychiatric Symptoms of 22q11.2 Deletion Syndrome
PHILADELPHIA, Sept. 9,...
Medgenics to Present at 22nd Annual NewsMakers in the Biotech Industry Conference
September 03, 2015 08:00 ET
|
Medgenics, Inc.
PHILADELPHIA, Sept. 3, 2015 (GLOBE NEWSWIRE) -- Medgenics, Inc. (NYSE:MDGN), the developer of a proprietary platform for the sustained production and delivery of therapeutic proteins and peptides in...
Medgenics Reports Second Quarter 2015 Financial Results
August 10, 2015 08:00 ET
|
Medgenics, Inc.
Initiated enrollment in peritoneal dialysis study in U.S.
Awarded $3.4 million grant from the Israeli Office of the Chief Scientist
Advanced collaboration activities with...
Medgenics Announces First Patient Enrolled in U.S.-Based Phase 2 Clinical Trial of TARGT-EPO for Treatment of Anemia in ESRD Patients Undergoing Peritoneal Dialysis
July 15, 2015 08:00 ET
|
Medgenics, Inc.
PHILADELPHIA, July 15, 2015 (GLOBE NEWSWIRE) -- Medgenics, Inc. (NYSE:MDGN), the developer of a proprietary platform for the sustained production and delivery of therapeutic proteins and peptides in...
Medgenics Added to RUSSELL 3000(R) and Global Indexes
June 29, 2015 08:00 ET
|
Medgenics, Inc.
PHILADELPHIA, June 29, 2015 (GLOBE NEWSWIRE) -- Medgenics, Inc. (NYSE MKT:MDGN), the developer of a proprietary platform for the sustained production and delivery of therapeutic proteins and peptides...
Medgenics to Present at JMP Securities Life Sciences Conference 2015
June 17, 2015 16:01 ET
|
Medgenics, Inc.
PHILADELPHIA, June 17, 2015 (GLOBE NEWSWIRE) -- Medgenics, Inc. (NYSE MKT:MDGN), the developer of a proprietary platform for the sustained production and delivery of therapeutic proteins and peptides...
Medgenics Awarded $3.4 Million Grant From the Israeli Office of the Chief Scientist
June 11, 2015 08:30 ET
|
Medgenics, Inc.
PHILADELPHIA, June 11, 2015 (GLOBE NEWSWIRE) -- Medgenics, Inc. (NYSE MKT:MDGN), the developer of a proprietary platform for the sustained production and delivery of therapeutic proteins and peptides...
Medgenics Announces Appointment of Barbara Duncan to Board of Directors
June 10, 2015 08:30 ET
|
Medgenics, Inc.
PHILADELPHIA, June 10, 2015 (GLOBE NEWSWIRE) -- Medgenics, Inc. (NYSE MKT:MDGN), the developer of a proprietary platform for the sustained production and delivery of therapeutic proteins and peptides...
Medgenics to Present Clinical Data at the 20th Congress of the European Hematology Association
June 04, 2015 08:30 ET
|
Medgenics, Inc.
- New Data Presented from Ongoing Phase 1/2 Study of TARGTEPOTM
PHILADELPHIA, June 4, 2015 (GLOBE NEWSWIRE) -- Medgenics, Inc. (NYSE MKT:MDGN), the developer of a proprietary platform for the...